Nexavar (sorafenib tosylate) — United Healthcare

Initial criteria

• Diagnosis of hepatocellular carcinoma
• AND one of the following:
• Patient has metastatic disease OR Patient has extensive liver tumor burden OR Patient is inoperable by performance status or comorbidity (local disease or local disease with minimal extrahepatic disease only) OR (Patient is not a transplant candidate AND Disease is unresectable)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Nexavar therapy

Approval duration

12 months